Clinical trial
Levofloxacin For The Management Of Patients With Abnormal Prostate Specific…
NCT00169585 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00169585 |
|---|---|
| Title | Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) |
| Official title | A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostatic Hyperplasia, Prostatitis |
| Intervention type | Drug |
| Interventions | Levofloxacin oral tablets |
| Enrollment | 240 |
| Start date | Mar 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | May 30, 2017 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: